Dolutegravir 50mg Tablet
Trade Name
Prescriber Category
:
:
A*
Department
Antimicrobial Restriction
:
:
ID
N/A
INDICATION (BLUE BOOK / UKK)
Dolutegravir is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age. Restriction: For patients who are not able to tolerate or failing treatment or resistance to the first line therapy (efavirenz and nevirapine).
DOSING FOR ADULTS GUIDE [DIAMS HSgB]
Usual dose:
50 mg PO q24h
Second line treatment in INSTI-experienced patients with suspected/confirmed INSTI-associated resistance:
50 mg PO q12h
Co-administration with EFV or Rifampicin:
50 mg PO q12h
RENAL DOSE ADJUSTMENT IN ADULTS GUIDE [DIAMS HSgB]
No dosage adjustment required.
IV TO PO GUIDE [DIAMS HSgB]
N/A
EXTENDED INFUSION GUIDE [DIAMS HSgB]
In-progress
SPECIAL MONITORING & PRECAUTION GUIDE [DIAMS HSgB]
In-progress
ALTERNATIVE DOSING (BLUE BOOK / HSgB DRUG LIST)
i) HIV-1 patients without documented or clinically suspected resistance to the integrase class: 50 mg (one tablet), once daily, orally. ii) HIV-1 patients with resistance to the integrase class: 50 mg (one tablet), twice daily, orally.